دورية أكاديمية
Comparing ICU admission rates of mild/moderate COVID-19 patients treated with hydroxychloroquine, favipiravir, and hydroxychloroquine plus favipiravir.
| العنوان: | Comparing ICU admission rates of mild/moderate COVID-19 patients treated with hydroxychloroquine, favipiravir, and hydroxychloroquine plus favipiravir. |
|---|---|
| المؤلفون: | Guner R; Department of Infectious Disease and Clinical Microbiology, Ankara Yildirim Beyazit University, Ankara City Hospital, Ankara, Turkey. Electronic address: rahmetguner@yahoo.com., Hasanoglu I; Department of Infectious Disease and Clinical Microbiology, Ankara Yildirim Beyazit University, Ankara City Hospital, Ankara, Turkey. Electronic address: imran.solak@gmail.com., Kayaaslan B; Department of Infectious Disease and Clinical Microbiology, Ankara Yildirim Beyazit University, Ankara City Hospital, Ankara, Turkey. Electronic address: drbican@gmail.com., Aypak A; Department of Infectious Disease and Clinical Microbiology, Ankara City Hospital, Ankara, Turkey. Electronic address: aadalet@yahoo.com., Akinci E; Department of Infectious Disease and Clinical Microbiology, University of Health Sciences, Ankara City Hospital, Ankara, Turkey. Electronic address: esragulakinci@gmail.com., Bodur H; Department of Infectious Disease and Clinical Microbiology, University of Health Sciences, Ankara City Hospital, Ankara, Turkey. Electronic address: hurrembodur@gmail.com., Eser F; Department of Infectious Disease and Clinical Microbiology, Ankara Yildirim Beyazit University, Ankara City Hospital, Ankara, Turkey. Electronic address: fatmacivelekeser@hotmail.com., Kaya Kalem A; Department of Infectious Disease and Clinical Microbiology, Ankara Yildirim Beyazit University, Ankara City Hospital, Ankara, Turkey. Electronic address: dr.aysekaya09@hotmail.com., Kucuksahin O; Department of Rheumatology, Ankara Yildirim Beyazit University, Ankara City Hospital, Ankara, Turkey. Electronic address: orhankcs@gmail.com., Ates I; Department of Internal Medicine, Ankara City Hospital, Ankara, Turkey. Electronic address: dr.ihsanates@hotmail.com., Bastug A; Department of Infectious Disease and Clinical Microbiology, University of Health Sciences, Ankara City Hospital, Ankara, Turkey. Electronic address: dr.aliye@yahoo.com., Tezer Tekce Y; Department of Infectious Disease and Clinical Microbiology, Ankara City Hospital, Ankara, Turkey. Electronic address: ayasmintezer@gmail.com., Bilgic Z; Department of Infectious Disease and Clinical Microbiology, Ankara City Hospital, Ankara, Turkey. Electronic address: zeynepunsal3860@gmail.com., Gursoy FM; Department of Infectious Disease and Clinical Microbiology, Ankara City Hospital, Ankara, Turkey. Electronic address: mlsgursoy@gmail.com., Akca HN; Department of Infectious Disease and Clinical Microbiology, Ankara City Hospital, Ankara, Turkey. Electronic address: htcnskc@gmail.com., Izdes S; Department of Anaesthesiology and Reanimation, Ankara Yildirim Beyazit University, Ankara City Hospital, Ankara, Turkey. Electronic address: sevalizdes@yahoo.com., Erdem D; Department of Anaesthesiology and Reanimation, Ankara City Hospital, Ankara, Turkey. Electronic address: dh2erdem@gmail.com., Asfuroglu E; Department of Internal Medicine, Ankara City Hospital, Ankara, Turkey. Electronic address: emra.kalkan@hotmail.com., Hezer H; Department of Pulmonary Diseases, Ankara City Hospital, Ankara, Turkey. Electronic address: hoflaz@yahoo.com., Kilic H; Department of Pulmonary Diseases, Ankara Yildirim Beyazit University, Ankara City Hospital, Ankara, Turkey. Electronic address: drhaticeb@yahoo.com., Cıvak M; Department of Internal Medicine, Ankara City Hospital, Ankara, Turkey. Electronic address: drhgk@hotmail.com., Aydogan S; Department of Virology, Ankara City Hospital, Ankara, Turkey. Electronic address: drsaydogan72@gmail.com., Buzgan T; Department of Infectious Disease and Clinical Microbiology, Ankara Yildirim Beyazit University, Ankara City Hospital, Ankara, Turkey. Electronic address: turanbuzgan@yahoo.com. |
| المصدر: | Journal of infection and public health [J Infect Public Health] 2021 Mar; Vol. 14 (3), pp. 365-370. Date of Electronic Publication: 2020 Dec 29. |
| نوع المنشور: | Journal Article; Observational Study |
| اللغة: | English |
| بيانات الدورية: | Publisher: Elsevier Country of Publication: England NLM ID: 101487384 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1876-035X (Electronic) Linking ISSN: 18760341 NLM ISO Abbreviation: J Infect Public Health Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Oxford : Elsevier, 2008- |
| مواضيع طبية MeSH: | Amides*/therapeutic use , Antiviral Agents*/therapeutic use , Hydroxychloroquine*/therapeutic use , Pyrazines*/therapeutic use , COVID-19 Drug Treatment*, Intensive Care Units/*statistics & numerical data, Adult ; Aged ; Aged, 80 and over ; Drug Therapy, Combination ; Female ; Humans ; Male ; Middle Aged ; Retrospective Studies ; Treatment Outcome ; Young Adult |
| مستخلص: | Background: In this study, we aimed to compare the intensive care unit (ICU) admission rate of hospitalized mild/moderate COVID-19 patients treated with hydroxychloroquine (HCQ), favipiravir, and HCQ plus favipiravir. Methods: Single center retrospective designed observational study conducted in Ankara City Hospital. Patients who were hospitalized between March 15, 2020 and June 1, 2020 in COVID-19 inpatient clinics with laboratory confirmed diagnosis of COVID-19 were included in the study. An inverse probability of treatment weighting (IPTW) for multiple treatment groups approach was used to balance the differences in several variables on admission. Results: Among 2441 patients hospitalized with diagnosis of COVID-19 during the study period, 824 were eligible for the analysis. Median age of patients was 42 (18-93 years). Among all, 347 (43.2%) of the patients had mild disease, 470 (56.8%) had pneumonia. Propensity scores ranged from 0.1841 to 0.9381 in the HCQ group, from 0.03643 to 0.29885 in the favipiravir group, and from 0.03542 to 0.56184 in the HCQ plus favipiravir group. After IPTW for multiple treatment groups was applied, all the covariates in the planned propensity score had weighted standardized effect sizes below 10% which were ranged from 0.005 to 0.092. Multivariate analysis of treatment effect (adjusted effect of treatment) was indicated that there is no statistically significant difference between HCQ, favipiravir, and HCQ plus favipiravir treatment. After using combination of SMOTE and Bootstrap resampling approach, we found no statistically significant difference between HCQ and HCQ plus favipiravir groups in terms of ICU admission. However, compared with the HCQ group, ICU admission rate was statistically significantly higher in the favipiravir group. We obtained the similar results after the sensitivity analysis. Conclusions: HCQ with or without favipiravir treatment is associated with reduced risk of ICU admission compared to favipiravir alone in mild to moderate COVID-19 adult patients. (Copyright © 2021 The Authors. Published by Elsevier Ltd.. All rights reserved.) |
| التعليقات: | Comment in: J Infect Public Health. 2022 Jan;15(1):68. (PMID: 34922225) |
| References: | Eur J Intern Med. 2020 Dec;82:38-47. (PMID: 32859477) Cell Res. 2020 Mar;30(3):269-271. (PMID: 32020029) Biosci Trends. 2020 Mar 16;14(1):72-73. (PMID: 32074550) JAMA. 2020 Jun 23;323(24):2493-2502. (PMID: 32392282) JAMA Netw Open. 2020 Apr 24;3(4):e208857. (PMID: 32330277) J Mol Cell Biol. 2020 May 18;12(4):322-325. (PMID: 32236562) Chin Med J (Engl). 2020 May 5;133(9):1087-1095. (PMID: 32358325) Clin Infect Dis. 2021 Dec 6;73(11):e4073-e4081. (PMID: 32674126) N Engl J Med. 2020 Jun 18;382(25):2411-2418. (PMID: 32379955) BMJ. 2020 May 14;369:m1849. (PMID: 32409561) Int J Antimicrob Agents. 2020 Oct;56(4):106144. (PMID: 32853673) Int J Infect Dis. 2020 Aug;97:396-403. (PMID: 32623082) Engineering (Beijing). 2020 Oct;6(10):1192-1198. (PMID: 32346491) Travel Med Infect Dis. 2020 Jul - Aug;36:101791. (PMID: 32593867) BMJ. 2020 May 14;369:m1844. (PMID: 32409486) Antimicrob Agents Chemother. 2020 Nov 17;64(12):. (PMID: 32958718) Clin Infect Dis. 2021 Aug 2;73(3):531-534. (PMID: 32770240) |
| فهرسة مساهمة: | Keywords: COVID-19; Favipiravir; Hydroxychloroquine; ICU; Treatment |
| المشرفين على المادة: | 0 (Amides) 0 (Antiviral Agents) 0 (Pyrazines) 4QWG6N8QKH (Hydroxychloroquine) EW5GL2X7E0 (favipiravir) |
| تواريخ الأحداث: | Date Created: 20210301 Date Completed: 20210330 Latest Revision: 20231110 |
| رمز التحديث: | 20240628 |
| مُعرف محوري في PubMed: | PMC7771901 |
| DOI: | 10.1016/j.jiph.2020.12.017 |
| PMID: | 33647553 |
| قاعدة البيانات: | MEDLINE |
Full Text via ClinicalKey 
Full Text Finder | تدمد: | 1876-035X |
|---|---|
| DOI: | 10.1016/j.jiph.2020.12.017 |